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Abstract
Background: Hormone replacement therapy (HRT) is often seen as the treatment of choice for
preventing fractures in women. We undertook a recent meta-analysis of randomised trials which
suggested that HRT reduced non-vertebral fractures by 30%. In this analysis we extend that analysis
to vertebral fractures.
Methods: We searched the main electronic databases until the end of August 2001. We sought
all randomised controlled trials (RCTs) of HRT where women had been randomised to at least 12
months of HRT or to no HRT.
Results: We found 13 RCTs. Overall there was a 33% reduction in vertebral factures (95%
confidence interval (CI) 45% to 98%).
Conclusions: This review and meta-analysis showed a significant reduction in vertebral fractures
associated with HRT use.
Background
Hormone replacement therapy (HRT) is often consid-
ered to reduce vertebral fractures by about 60% [1]. This
view is based upon the results of one trial, which counted
the number of fractures rather than the number of wom-
en with fractures. If an analysis is undertaken looking at
the number of women with an incident vertebral fracture
the reduction is less and is not statistically significant [2].
We have recently reported in a systematic review of 22
randomised-controlled trials that hormone replacement
therapy (HRT) reduces non-vertebral fractures by about
30% [3]. To see if there were a similar effect on vertebral
fractures we have extended our review to include such
fractures.
Methods
Our search strategy has been previously reported; [3]
however, in brief, we searched all the main electronic da-
tabases for any RCT of HRT and contacted investigators
for unpublished data. There were no language restric-
tions. To be included in the review trials had to be longer
than 12 months and include a comparator group who
were either taking an inactive placebo, calcium with or
without vitamin D, or using no treatment. Up until the
end of August 2001, after excluding duplicate reports, we
identified 72 potentially relevant trials.
Results
We identified 13 eligible studies. Nine of which came
from our original review of 22 trials [4–12]. The four ad-
ditional trials, not previously included, were identified as
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follows. Two trials were excluded from our previous re-
view as they only reported vertebral fractures [1,13] and
are now included and two further studies were identified
in a recent update of our search [14,15]. We combined
the trials in a meta-analysis using a random effects mod-
el.
We assessed 12 studies for quality, the remaining study
being available in abstract form only [15]. Trial quality
was generally good. All studies were reported as ran-
domised controlled trials with seven reporting the meth-
od of randomisation used. In addition nine trials were
double blind by design and almost all trials reported on
drop-outs or withdrawals and document the reasons for
these events.
The table shows the characteristics of the included trials.
Eight [1,7,10–15] of the 13 studies assessed fracture inci-
dence using radiographs whilst the remaining five ap-
peared to report only symptomatic fractures.
Figure 1 shows the number of women in each treatment
group and their relative risk of fracture. As the figure
shows there was an approximate 33% reduction in verte-
bral fractures among women randomised to HRT (p =
0.04). Three of the studies were undertaken among
women who had established osteoporosis [1,11,15]. The
relative risk of fracture among these women was 0.47
(95% CI 0.25 to 0.89, p = 0.02), whilst the relative risk of
the 10 trials among women without osteoporosis was
0.81 (95% CI 0.50 to 1.33, p = 0.40). Five trials were un-
dertaken among women with a mean age of less than 60
years [5,7–9,13]: the pooled relative risk of fracture for
these women was 0.61 (95% CI 0.16 to 2.36), whilst for
women older than 60 years it was 0.63 (95%CI 0.41 to
0.96).
Discussion
This review of the effects of HRT on vertebral fractures
showed a similar reduction in events as did our previous
analysis on non-vertebral fractures. As in our previous
review the quality of the trials was generally good [3].
Our previous review noted a decreasing effect of HRT on
non vertebral fractures for women starting therapy when
older than 60 years [3]. In this study we did not observe
a similar relationship. Although the relative risk of frac-
Table 1: Description of HRT Trials.
Study Length 
months
Type of Oestrogen Progestin+ 
Addition of 
calcium*
Study Population Outcome 
measure
Age (SD/
range)
Alexandersen 1999 
[12]
22 50-ug transdermal estradiol +* Healthy postmenopausal women 
with low BMD
BMD 65 (2.2)
Delmas 2000 [5] 24 Oral 1 mg estradiol +* Healthy >1 year postmenopausal 
women with normal BMD.
BMD 58 (5)
Gallagher 2001 [14] 36 Oral 0.625 mg conjugated estrogens +* Elderly women with normal bone 
density
BMD 72(± 4)
Cauley 2001 [4] 49 Oral 0.625 conjugated estrogen + Women with established coronary 
disease >5 years post menopause
MI or 
CHD
67
Herrington 2000 
[6]
38 Oral 0.625 conjugated estrogen + Women with coronary arterial dis-
ease (CAD)
CAD Pro-
gression
66 (7.0)
Ishida 2001 [15] 12 Oral 0.625 conjugated estrogen. + Women with established oste-
oporosis.
BMD 70 (7.6)
Lindsay 1990 [13] 24 Oral 0.625 mg conjugated estrogen +* Postmenopausal women with 1+ 
vertebral fracture & low BMD
BMD 48 (1.0)
Lufkin 1992 [1] 12 Transdermal 0.1 mg 17β -estradiol + Postmenopausal white women with 
documented osteoporosis
BMD 64.8 (54.9 
to 71.3)
Mosekilde 2000 [7] 60 Oral 1 mg or 2 mg estradiol + Healthy women 3–24 months post 
menopause
Fractures 50 (2.8)
PEPI 1996 [8] 36 Oral 0.625 mg conjugated estrogen + Healthy women 1–10 years post 
menopause normal BMD
BMD 56 (0.3)
Ravn 1999 [9] 48 Oral 0.625 conjugated estrogen or 
2 mg estradiol
+ Healthy 6+ months postmenopausal 
women under 60 years
BMD 55
Recker 1999 [10] 42 0.3 mg conjugated estrogen +* Healthy women average BMD t-
score-3.5 at femur
BMD 73 (5.0)
Wimalawansa 1998 
[11]
48 Oral 0.625 conjugated estrogen +* Women with established oste-
oporosis (1+vertebral fracture)
BMD 65 (0.9)BMC Musculoskeletal Disorders 2001, 2:7 http://www.biomedcentral.com/1471-2474/2/7
ture reduction for younger women was not statistically
significant it was virtually identical to that for older
women (i.e RR = 0.61 and 0.63 for younger and older
women respectively). There were fewer events and fewer
participants in trials among women with a mean age of
less than 60 years and this may explain the lack of statis-
tical significance.
Studies of other anti-fracture drugs, such as the bisphos-
phonates, have suggested an enhanced effect among pa-
tients with established osteoporosis [16]. This review
may support an interaction between HRT and the pres-
ence of osteoporosis on vertebral fracture incidence, al-
though the number of trials in that sub-group are small,
so definitive conclusions cannot be drawn on this issue.
This may be a chance finding, however, because our pre-
vious review, where nearly all included women were not
osteoporotic, showed an HRT effect on non-vertebral
fractures [3]. With respect to the effects, or otherwise, of
HRT among women who have low bone density without
a prior vertebral fracture there were no studies that al-
lowed us to explore HRT's effects on this sub-group.
Interestingly, taking the results of this review along with
our previous analysis shows a similar effect on fractures
as the large RCT of the Selective Estrogen Receptor Mod-
ulator (SERM) raloxifene [17]. In that trial, among wom-
en with a mean age of 67 years, a 50% reduction in new
vertebral fractures was observed among osteoporotic
women whilst a small, non-significant reduction in non-
vertebral fractures was observed [17]. The issue as to
whether HRT does significantly reduce vertebral and
other fractures needs to be tested in large randomised
trials with fracture as an endpoint. Fortunately, ongoing
trials of HRT are large enough to answer this important
question.
Conclusion
In summary, our review has shown that HRT use is asso-
ciated with reduction in vertebral fractures, particularly
among osteoporotic women.
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